Press Release: Novartis receives positive CHMP -2-

References

1. Proud C, et al. Nature Medicine. 2025.

https://doi.org/10.1038/s41591-025-04103-w

2. Clinicaltrials.Gov. STRENGTH Study Results.

https://clinicaltrials.gov/study/NCT05386680. Accessed February 2026.

3. Finkel, R S et al. J. Neuromuscul. Dis. 2023;10,3:389-404.

4. Anderton RS and Mastaglia FL. Expert Rev Neurother. 2015;15(8):895--908.

5. National Organization for Rare Disorders (NORD). Spinal Muscular Atrophy.

https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. Accessed

November 2025.

6. Lorson CL, et al. Hum Mol Genet. 2010;(15):111-8.

7. Verhaart IEC, et al. Orphanet J Rare Dis. 2017.

https://doi.org/10.1186/s13023-017-0671-8.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations Central investor

relations line: +41 61 324 7944 E-mail:

investor.relations@novartis.com

(END) Dow Jones Newswires

April 24, 2026 06:30 ET (10:30 GMT)